4D Molecular Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $1 | $3 | $5 | $28 |
Gross Profit | 3,219 | 3 | -1,619 | -1,566 |
EBITDA | -61,038 | -49,429 | -40,832 | -36,542 |
EBIT | -56,117 | -51,132 | -42,456 | -38,136 |
Net Income | -49,671 | -43,843 | -34,953 | -32,401 |
Net Change In Cash | 1 | 3 | 5 | 28 |
Free Cash Flow | -46,812 | -28,332 | -30,592 | -29,798 |
Cash | 149,336 | 187,539 | 189,061 | 275,594 |
Basic Shares | 53,943 | 55,554 | 55,282 | 49,271 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $37 | $20,723 | $3,129 | $18,038 |
Gross Profit | 37 | -76,373 | 3,129 | 18,038 |
EBITDA | -187,841 | -107,118 | -106,152 | -68,313 |
EBIT | -112,867 | -110,032 | -71,333 | |
Net Income | -160,868 | -100,837 | -101,076 | -68,297 |
Net Change In Cash | 37 | 20,723 | 3,129 | 18,038 |
Cost of Revenue | -100,650 | -123,725 | ||
Free Cash Flow | -134,585 | -78,563 | -98,221 | -78,244 |
Cash | 149,336 | 249,108 | 218,642 | 315,429 |
Basic Shares | 53,943 | 39,130 | 32,351 | 27,730 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.90 |
2024-09-30 | -$0.79 |
2024-06-30 | -$0.63 |
2024-03-31 | -$0.66 |
